Search Patents
  • Coronavirus vaccine compositions, methods, and uses thereof
    Patent number: 11389528
    Abstract: The present disclosure relates in some aspects to immunogenic compositions including recombinant peptides and proteins comprising coronavirus viral antigens and immunogens, e.g., coronavirus S protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble coronavirus viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing a coronavirus infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and/or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and/or diagnostic methods, and related kits.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: July 19, 2022
    Assignee: Sichuan Clover Biopharmaceuticals, Inc
    Inventors: Peng Liang, Joshua Liang
  • Cold-adapted live attenuated severe acute respiratory syndrome coronavirus and vaccine containing the same
    Patent number: 11020475
    Abstract: Disclosed is cold-adapted live attenuated severe acute respiratory syndrome coronavirus (SARS-CoV-2) prepared by infecting cells with severe acute respiratory syndrome coronavirus and then adapting the severe acute respiratory syndrome coronavirus to a temperature from 37° C. to 22° C. in a step by step manner. Further, a vaccine containing the cold-adapted live attenuated severe acute respiratory syndrome coronavirus (SARS-CoV-2) is disclosed.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: June 1, 2021
    Assignee: The Industry & Academic Cooperation in Chungnam National University (IAC)
    Inventors: Sang-Heui Seo, Yun-Yueng Jang
  • CORONAVIRUS VACCINE
    Publication number: 20240042011
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: March 20, 2023
    Publication date: February 8, 2024
    Inventors: Alexander Muik, Asaf Poran, Kena Anne Swanson, Qi Yang, Hui Cai, Ugur Sahin
  • CORONAVIRUS VACCINE
    Publication number: 20230338512
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: November 29, 2022
    Publication date: October 26, 2023
    Inventors: Alexander Muik, Asaf Poran, Kena Anne Swanson, Qi Yang, Hui Cai
  • NUCLEIC ACID VACCINES FOR CORONAVIRUS
    Publication number: 20240131150
    Abstract: Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses.
    Type: Application
    Filed: December 1, 2023
    Publication date: April 25, 2024
    Inventor: Bo Ying
  • CORONAVIRUS DISEASE 2019 (COVID-19) COMBINATION VACCINE
    Publication number: 20230210981
    Abstract: Disclosed herein is a vaccine comprising a Coronavirus disease 2019 (COVID-19) antigen in a combination with an immunoglobulin from post-exposure treatment. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
    Type: Application
    Filed: June 9, 2021
    Publication date: July 6, 2023
    Inventors: David Weiner, Ami Patel
  • CORONAVIRUS VACCINE
    Publication number: 20230075979
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: March 18, 2022
    Publication date: March 9, 2023
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • METHOD FOR IMPROVING ANTIGEN IMMUNOGENICITY, CORONAVIRUS ANTIGEN, USE THEREOF, RECOMBINANT VECTOR, EXPRESSION KIT, TRANSGENIC CELL LINE, RECOMBINANT BACTERIUM, CORONAVIRUS VACCINE, PREPARATION METHOD OF ANTIGEN AND NUCLEOTIDE SEQUENCE
    Publication number: 20230173057
    Abstract: Provided is a Helicobacter pylori ferritin-based novel coronavirus S protein single-region subunit nano-vaccine. According to the present invention, a receptor binding domain (RBD) of a virus is used as an antigen and is connected with a Helicobacter pylori multimeric protein (HP_Ferritin) to form a fusion protein RBD-HP_Ferritin, such that antigen multimerization is realized; and an eukaryotic cell expression system is then utilized for expression, so as to form a 24-mer nano-antigen by means of the self-assembly action of the HP_Ferritin. According to the solution, the defect that RBD monomers are insufficient in immunogenicity can be overcome; the obtained vaccine can remarkably improve the level of neutralizing antibodies of a host to viruses; and the generated antibodies have the capacity to strongly prevent the viruses from invading target cells.
    Type: Application
    Filed: March 30, 2020
    Publication date: June 8, 2023
    Applicant: GUANGZHOU QIANYANG BIO-TECHNOLOGY PHARMACEUTICAL CO., LTD.
    Inventors: Hui ZHANG, Xiancai MA, Fan ZOU, Yaochang YUAN, Rong LI, Xu ZHANG
  • NUCLEIC ACID VACCINES FOR CORONAVIRUS
    Publication number: 20240042010
    Abstract: Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses.
    Type: Application
    Filed: November 2, 2022
    Publication date: February 8, 2024
    Inventor: Bo Ying
  • NUCLEIC ACID VACCINES FOR CORONAVIRUS
    Publication number: 20220218816
    Abstract: Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses.
    Type: Application
    Filed: January 31, 2022
    Publication date: July 14, 2022
    Inventor: Bo Ying
  • NUCLEIC ACID VACCINES FOR CORONAVIRUS
    Publication number: 20230277652
    Abstract: Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses.
    Type: Application
    Filed: November 1, 2022
    Publication date: September 7, 2023
    Inventor: Bo Ying
  • FUSION GENE, RECOMBINANT NOVEL CORONAVIRUS HIGH-EFFICIENCY IMMUNE DNA VACCINE, CONSTRUCTION METHOD AND USE THEREOF
    Publication number: 20230355742
    Abstract: A fusion gene, a recombinant novel coronavirus high-efficiency immune DNA vaccine, a construction method and use thereof are provided. The immune DNA vaccine ZD-nCor19 provided herein uses RBD protein, residues 301-538 in the S2 subunit and residues 138-369 in the N protein of the novel coronavirus as target antigens, and has specific immune synergism molecules introduced at suitable positions, and thus can simultaneously efficiently induce humoral immunity and cellular immunity, and can avoid safety problems associated with ADE that may be generated by the full-length S protein and the full-length N protein, thereby achieving dual effects of prevention and treatment. The vaccine can be used as a safe, efficient and stable vaccine variety against novel coronavirus infection.
    Type: Application
    Filed: November 19, 2021
    Publication date: November 9, 2023
    Applicant: Aurora Genevac Biotech Co., Ltd.
    Inventors: Jiyun YU, Yu WANG, Weiwei SONG, Jinqi YAN, Qiang XU, Yu XIA, Yachao LIU, Kun GAO, Chuang-Jiun CHIOU
  • CORONAVIRUS VACCINE
    Publication number: 20230073461
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: March 18, 2022
    Publication date: March 9, 2023
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20210228708
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: February 8, 2021
    Publication date: July 29, 2021
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20210228709
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: March 18, 2021
    Publication date: July 29, 2021
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20230330216
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: December 5, 2022
    Publication date: October 19, 2023
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • CORONAVIRUS VACCINE
    Publication number: 20240075165
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: November 16, 2022
    Publication date: March 7, 2024
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20220332765
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: March 22, 2022
    Publication date: October 20, 2022
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20220125914
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: January 10, 2022
    Publication date: April 28, 2022
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • Coronavirus vaccine
    Patent number: 11547673
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: January 10, 2023
    Assignee: BioNTech SE
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
Narrow Results

Filter by US Classification